Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical studies on phosphate handling in hypercalcaemia.

B Wikström, S Ljunghall, L Wide

    Acta Medica Scandinavica
    |January 1, 1982
    PubMed
    Summary

    This study examined how the body handles phosphate in patients with high blood calcium levels. Researchers looked at phosphate levels in the blood and urine, along with other indicators, in 88 patients with hypercalcaemia. Of these, 64 had primary hyperparathyroidism and 24 had other causes, mostly cancer. The study found that phosphate levels could clearly separate patients with hyperparathyroidism from those with normal or low parathyroid function. However, these same phosphate measures did not help tell the difference between hyperparathyroidism and cancer-related hypercalcaemia. The researchers also found that patients with hyperparathyroidism had high levels of parathyroid hormone, while those with cancer-related hypercalcaemia had normal levels. In cancer patients, higher levels of a substance called cAMP were linked to higher calcium levels and lower phosphate reabsorption. These findings suggest that something in the blood—possibly a hormone-like substance—may be causing the high calcium in cancer patients. The study also found no difference in phosphate measures between patients with and without kidney stones, suggesting that stone formation does not affect phosphate handling in hyperparathyroidism.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Variable p-glycoprotein immunoreactivity unrelated to cytotoxic drug-resistance in-vitro of human adrenocortical carcinoma.

    International journal of oncology·2011
    Same author

    Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.

    Gene therapy·2011
    Same author

    Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    Annals of oncology : official journal of the European Society for Medical Oncology·2010
    Same author

    Stathmin as a marker for malignancy in pheochromocytomas.

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2009
    Same author

    World apheresis registry 2003-2007 data.

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2008
    Same author

    Activated beta-catenin in the novel human parathyroid tumor cell line sHPT-1.

    Biochemical and biophysical research communications·2006

    Area of Science:

    • Endocrinology and metabolic disorders
    • Renal physiology
    • Clinical diagnostics in hypercalcaemia

    Background:

    Hypercalcaemia presents diagnostic challenges due to overlapping clinical features across different etiologies. Phosphate handling in the kidney is a key indicator of underlying pathophysiology in hypercalcaemic states. Prior research has shown that phosphate indices can distinguish between normal and abnormal parathyroid function. However, no prior work had resolved how these indices perform in differentiating hyperparathyroidism from other causes of hypercalcaemia. This gap motivated a study to evaluate phosphate variables in patients with primary hyperparathyroidism versus those with malignancy-related hypercalcaemia. Established knowledge includes the role of parathyroid hormone in regulating phosphate excretion and reabsorption. That uncertainty drove the investigation into whether phosphate indices could aid in differential diagnosis. The study aimed to clarify if these indices could reliably separate hyperparathyroidism from other hypercalcaemic conditions.

    Purpose Of The Study:

    Keywords:
    Hypercalcaemia diagnosisPhosphate excretionParathyroid hormone levelsRenal phosphate reabsorptionClinical endocrinology

    Frequently Asked Questions

    The study evaluated serum phosphate, tubular reabsorption, TmP/GFR, and excretion index in hypercalcaemic subjects.

    Phosphate indices distinguished hyperparathyroidism from normal subjects but not from malignancy-related cases.

    A positive correlation between cAMP and serum calcium suggested a PTH-like humoral factor in malignant disease.

    Hyperparathyroidism patients had elevated PTH, while malignancy patients had normal PTH concentrations.

    Related Experiment Videos

    The study aimed to assess phosphate handling indices in hypercalcaemic patients to differentiate primary hyperparathyroidism from other causes. Researchers focused on serum phosphate, tubular reabsorption, and excretion indices in 88 hypercalcaemic subjects. The goal was to determine if these variables could reliably distinguish hyperparathyroidism from malignancy-related hypercalcaemia. They also sought to evaluate the relationship between cAMP and phosphate indices in malignant disease. The motivation stemmed from the need to improve diagnostic accuracy in hypercalcaemic patients. This approach could refine clinical decision-making by identifying specific phosphate patterns. The study did not aim to propose new treatment strategies but to enhance diagnostic differentiation. The authors sought to clarify whether phosphate indices could support or challenge existing diagnostic criteria.

    Main Methods:

    The study involved 88 hypercalcaemic subjects categorized into primary hyperparathyroidism and other causes. Phosphate indices included serum phosphate, tubular reabsorption, TmP/GFR, and excretion index. Researchers compared these indices between normal subjects, hyperparathyroidism patients, and those with malignancy. Urinary cAMP levels and serum PTH concentrations were also measured for each group. Statistical analysis focused on correlations between cAMP, serum calcium, and TmP/GFR in malignant disease. No invasive procedures were used; all data came from standard clinical assessments. The study did not involve experimental interventions but relied on observational data. Findings were synthesized to evaluate the diagnostic utility of phosphate indices in hypercalcaemia.

    Main Results:

    Phosphate indices effectively distinguished hyperparathyroidism patients from normal subjects and hypoparathyroid patients. However, these indices showed little value in differentiating hyperparathyroidism from malignancy-related hypercalcaemia. Urinary cAMP excretion was similar between the two hypercalcaemic groups. Hyperparathyroidism patients had elevated serum PTH levels, while malignancy patients had normal PTH concentrations. A positive correlation was found between cAMP and serum calcium in malignant disease patients. An inverse relationship was observed between cAMP and TmP/GFR in this group. These findings suggest a PTH-like humoral factor may be active in malignant hypercalcaemia. No significant differences were found in phosphate variables between stone-forming and stone-free hyperparathyroidism patients.

    Conclusions:

    The authors concluded that phosphate indices are useful in distinguishing hyperparathyroidism from normal or hypoparathyroid states. However, these indices do not aid in differentiating hyperparathyroidism from malignancy-related hypercalcaemia. The presence of a PTH-like humoral factor in malignant disease was proposed based on cAMP correlations. Elevated PTH levels in hyperparathyroidism contrasted with normal PTH in malignancy-related cases. The study did not support the role of circulating PTH in mediating physiological effects in malignant disease. No differences were found in phosphate indices between stone-forming and stone-free hyperparathyroidism patients. The findings suggest that phosphate indices may not be sufficient for differential diagnosis in all hypercalcaemic cases. The authors emphasized the need for further investigation into humoral factors in malignant hypercalcaemia.

    No differences were found in phosphate variables between stone-forming and stone-free patients with HPT.

    The authors proposed the existence of a PTH-like humoral factor based on cAMP and TmP/GFR correlations.